Skip to content
Recall Observatory FDA recall evidence

Exact FDA event identifier

Event 95611

2 recalled-product records grouped only because every row carries this exact official event ID.

Open FDA event record

Event summary

Timeline bucket
October 23, 2024
Product types
Drug
Classifications
Class II
Statuses
Ongoing
Recalling firm wording
Cipla USA, Inc.

Dossier provenance

Source snapshots represented here

  • openFDA Drug Enforcement Report-date coverage June 20, 2012–July 08, 2026 Known gap: openFDA describes 2004-present coverage, but the current export has no report-date records in this interval.

Enforcement coverage uses report dates; product initiation dates can precede those bounds. Device-enrichment coverage uses FDA event_date_initiated.

How coverage and grouping work

Complete imported group

Every recalled product in this event

2 official enforcement rows

Product dates, classifications, firms, and source wording remain attached to their individual rows. Opening this dossier never hides products that did not match a prior timeline filter.

drug · product 1 of 2

Lanthanum Carbonate Chewable Tablets, 1000mg, 10-count bottle, Rx only, Manufactured for Cipla USA, NDC 69097-0936-98

D-0043-2025
Recall number
D-0043-2025
Initiated
October 23, 2024
Classification
Class II
Status
Ongoing
Recalling firm
Cipla USA, Inc.
Quantity
1,875 boxes (cipla and exlan)

App-derived interpretation

Unknown reason.no_named_rule · v1.0.0
Failed Tablet/Capsule Specifications: Complaints received of crushed and broken tablets.

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Failed Tablet/Capsule Specifications: Complaints received of crushed and broken tablets.

Code information

Lot # NB240316, Exp 12/31/25

Distribution pattern

USA nationwide.

drug · product 2 of 2

Lanthanum Carbonate Chewable Tablets, 1000mg, 10-count bottle, Rx only, Manufactured for Exelan Pharmaceuticals, NDC 76282-0478-90

D-0044-2025
Recall number
D-0044-2025
Initiated
October 23, 2024
Classification
Class II
Status
Ongoing
Recalling firm
Cipla USA, Inc.
Quantity
N/A

App-derived interpretation

Unknown reason.no_named_rule · v1.0.0
Failed Tablet/Capsule Specifications: Complaints received of crushed and broken tablets.

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Failed Tablet/Capsule Specifications: Complaints received of crushed and broken tablets.

Code information

Lot# NB240873, Exp 03/31/2026

Distribution pattern

USA nationwide.